Processes with terminal transferase, aminoxy nucleoside triphosphates, and nucleobase analogs

Abstract

This invention claims processes that comprise the appending of nucleotides having a 3-ONH.sub.2 moiety to the 3-ends of oligonucleotide primers using 3-deoxynucleoside triphosphates of 2-deoxynucleoside derivatives that have, instead of a 3-OH moiety, a 3-ONH.sub.2 moiety, where the nucleotides contain non-standard nucleobases.

Claims

1. A process for synthesizing an oligonucleotide that has a 3-ONH.sub.2 moiety instead of a 3-OH moiety, said process comprising contacting an oligodeoxyribonucleotide in an aqueous buffered solution with terminal deoxynucleotide transferase and a nucleoside triphosphate having the structure: ##STR00001## or one of its ionized forms, wherein B is a heterocycle selected from the group consisting of ##STR00002## wherein Su indicates the point of attachment of the heterocycle to the sugar, and wherein said solution contains less than 1 micromolar hydroxylamine.

2. A process for synthesizing an oligonucleotide that has a 3-ONH.sub.2 moiety instead of a 3-OH moiety, said process comprising contacting an oligodeoxyribonucleotide in an aqueous buffered solution with terminal deoxynucleotide transferase and a nucleoside triphosphate having the structure: ##STR00003## or one of its ionized forms, wherein B is a heterocycle selected from the group consisting of ##STR00004## wherein Su indicates the point of attachment of the heterocycle to the sugar, and R is either H, CH.sub.3, or a functionalized side chain; wherein said solution contains less than 1 micromolar hydroxylamine.

3. The process of claim 2, wherein said heterocycle is ##STR00005## wherein Su indicates the point of attachment of the heterocycle to the sugar, and R is either H, CH.sub.3, or a functionalized side chain.

4. The process of claim 2, wherein said heterocycle is ##STR00006## wherein Su indicates the point of attachment of the heterocycle to the sugar, and R is either CH3, or a functionalized side chain.

5. The process of claim 2, wherein B is ##STR00007## wherein Su indicates the point of attachment of the heterocycle to the sugar.

6. A process for synthesizing an oligonucleotide that has a 3-ONH.sub.2 moiety instead of a 3-OH moiety, said process comprising contacting an oligodeoxyribonucleotide in an aqueous buffered solution with terminal deoxynucleotide transferase and a nucleoside triphosphate having the structure: ##STR00008## or one of its ionized forms, wherein B is a heterocycle selected from the group consisting of ##STR00009## wherein Su indicates the point of attachment of the heterocycle to the sugar, wherein said solution contains less than 1 micromolar hydroxylamine.

Description

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S)

(1) FIG. 1. A polyacrylamide gel electrophoresis (PAGE) image showing the addition by terminal deoxynucleotide transferase (TdT) of a single nucleotide carrying a 3-ONH.sub.2 group in two different buffers to an oligonucleotide carrying a 5-phosphorus-32 label. External bands are ladders. The concentrations of the aminoxytriphosphates are shown below each lane, for the aminoxytriphosphate indicated at the top of each lane.

(2) FIG. 2: PAGE (16%) showing a time course of GTP-ONH.sub.2 incorporation using terminal transferase (TdT). Addition of a single nucleotide is complete at ca. 15 minutes. This preparation contains substantial amounts of dGTP having a free 3-OH group, as indicated by the second shadow band.

(3) FIG. 3. PAGE (20%) of aminoxy samples tested in terminal transferase reaction to extend a 5-radiolabeled primer. Lanes labeled a through g have different triphosphates as described in the text; incubation times are 5 and 50 minutes, as indicated.

(4) FIG. 4. PAGE (20%) of control and aminoxy triphosphates prepared as taught in U.S. patent application Ser. No. 15/460,475 tested in a terminal transferase reaction in two different buffers. This data set shows no significant impact of the presence of divalent cobalt cation in the incubation buffer.

(5) FIG. 5. Structures of the standard 3-aminoxytriphosphates of the instant invention.

(6) FIG. 6. Structures of the standard and non-standard 3-aminoxytriphosphates of the instant invention, where Su indicates the point of attachment of the heterocycle to the sugar, R is either H, CH.sub.3, or a functionalized side chain, and X is either N or CR.

(7) FIG. 7. PAGE (20%) of aminoxy reversibly terminated and irreversible triphosphate tested in terminal transferase reactions in the absence and presence of pyrophosphatase. Reactions were incubated for 15 and 60 min.

(8) FIG. 8. PAGE (20%) of dSTP-ONH.sub.2 without and with pyrophosphatase tested in terminal transferase reactions. Reactions were incubated for 15 and 60 min.

(9) FIG. 9. PAGE (20%) of extension of primers using terminal transferase and AEGIS nucleotides S (a pyrimidine analog presenting an acceptor-acceptor-donor hydrogen bonding pattern), B (a purine analog presenting a donor-donor-acceptor hydrogen bonding pattern) and P (a purine analog presenting a donor-donor-acceptor hydrogen bonding pattern). aminoxy samples (tested in terminal transferase reactions. Reactions were incubated for 15 and 60 min. The tailing oligo is 24 bases long. Left panel was loaded 2 L of samples; right panel was loaded 4 L of samples.

DETAILED DESCRIPTION OF THE INVENTION

(10) The invention disclosed here involves contacting an oligonucleotide in an appropriate buffer with an enzyme known as terminal deoxynucleotide transferase (TdT, or simply terminal transferase). Terminal transferase was discovered many years ago in calf thymus as an enzyme that adds nucleoside triphosphates to the 3-end of an oligonucleotide in an untemplated fashion.

(11) Some key references, which are incorporated herein by citation, are: Roychoudhury, R., Jay, E., Wu, R. (1976) Nucl. Acids Res. 3, 101-116. Tu, C. P., Cohen, S. N. (1980) Gene. 10, 177-183. Boule, J. B., Rougeon, F., Papanicolaou, C. (2001) J. Biol. Chem. 276, 31388-31393.

(12) The presently preferred terminal deoxynucleotidyl transferase (TdT) prefers DNA as an oligonucleotide substrate. Single ribonucleotide addition is seen with the native enzyme a slower rate. The presently preferred TdT is the enzyme that is commercially available, recently sold by New England Biolabs or Promega, or the analogous enzyme obtained from other mammalian thymus glands. Most preferred is a TdT or one of its variants containing 1-3 amino acid replacements obtained via recombinant DNA technology that is expressed in a host cell.

(13) The invention here comprises contacting of an oligonucleotide, preferably a 3-oligodeoxyribonucleotide, with a triphosphate, as disclosed in U.S. Pat. No. 8,034,923, carrying the 3-ONH.sub.2 moiety, in aqueous buffers where TdT operates. These buffers are well known in the art, and are provided in the examples below. The buffer may optionally contain divalent cobalt cation (Co.sup.++), which is known to improve the ability of the terminal transferase to accept standard pyrimidine nucleoside triphosphates. However, with the aminoxy analogs, we have discovered that Co.sup.++ does not improve the performance of TdT, at least in the buffers examined. Those buffers have preferable pH ranges from 7 to 8, but not outside pH 6 to 9. The preferable contact temperature is preferably between 25 C. and 40 C.

(14) The utility of the instant invention arises from its ability to at a single nucleotide at a time. This can be, for example, envisioned as a synthesis procedure, where an oligonucleotide having a defined, preselected, sequence is synthesized by contacting an immobilized primer with:

(15) (a) a nucleoside triphosphate having a 3-ONH.sub.2 moiety and carrying the nucleobase of the desired first nucleotide in the preselected sequence,

(16) (b) incubating for a period of time to allow the single nucleotide addition to go substantially to completion,

(17) (c) washing the incubation mixture from the immobilized primer which now has additional nucleotide and a blocked 3-end,

(18) (d) removing the 3-aminoxy block, for example, by treating with buffered sodium nitrite following the procedure described in U.S. Pat. No. 8,034,923 (Benner, S. A., Hutter, D., Leal, N. A., Chen, F. Reagents for Reversibly Terminating Primer extension. U.S. Pat. No. 8,034,923), which is incorporated in its entirety by reference, and

(19) (e) repeating the cycle for each additional desired nucleotide in the preselected sequence.

(20) For this and other applications where addition of precisely one nucleotide is desired, is preferred that the triphosphate having a 3-ONH.sub.2 moiety not be contaminated with triphosphates that have a standard, and extendable, 3-OH group. As shown in the examples, TdT has a preference for the natural triphosphate having an extendable 3-OH group. Indeed, TdT can be used to clean up preparations of triphosphates having a 3-ONH.sub.2 moiety by removing natural triphosphates having an extendable 3-OH group. For other applications, this contamination is tolerable.

(21) The most presently preferred triphosphates having a 3-ONH.sub.2 moiety are those prepared by the procedure disclosed in U.S. patent application Ser. No. 15/460,475, which is incorporated herein in its entirety by reference. These nucleoside triphosphates are substantially free of contaminating standard triphosphate, where substantially means that the preparation triphosphate carrying a 3-ONH.sub.2 moiety contains less than 0.5 mole percent of the analogous triphosphate with a free 3-OH group, more preferably less than 0.05 mole percent, and most preferably less than 0.005 mole percent, calculated relative to the triphosphate carrying a 3-ONH.sub.2 moiety. Further, as taught in U.S. patent application Ser. No. 15/460,475, in addition to the standard nucleoside triphosphates shown in FIG. 5, the nucleoside might carry an unnatural nucleobase, selected from the structures shown in FIG. 6.

EXAMPLES

Example 1

(22) The ability of terminal transferase to add a 3-aminoxy terminating triphosphate to oligonucleotides was discovered by a series of experiments. In these experiments, this oligonucleotide substrate was used:

(23) TABLE-US-00001 dhSSP1: SEQIDNO1 5-GCGTAATACGACTCACTATGGACG-3

(24) This oligonucleotide was 5-labeled to give

(25) TABLE-US-00002 5-.sup.32P-GCGTAATACGACTCACTATGGACG-3,
which is SEQ ID NO 1) using OptiKinase and gamma-labeled radioactive ATP.

(26) Two different buffers were used for the experiments that discovered the ability of terminal transferase to add a 3-aminoxy terminating triphosphate to oligonucleotides. The purine tailing buffer contained 100 mM cacodylate buffer (pH 7.1), 2 mM MnCl.sub.2, 0.1 mM DTT, 10 pmol of radiolabeled template (0.5 M), 10 units of Terminal Transferase, and varying amounts of reversible terminating triphosphates ranging from 5 M to 250 M (as indicated on gel). The total volume was 20 L.

(27) The pyrimidine tailing buffer contained 100 mM cacodylate buffer (pH 7.1), 2 mM CoCl.sub.2, 0.1 mM DTT, 10 pmol of radiolabeled template (0.5 M), 10 units of Terminal Transferase, and varying amounts of reversible terminator triphosphates from 5 M to 250 M. Again, the total volume was 20 L.

(28) Samples were incubated at 37 C. for 1 hour. Then, the transferase reaction was terminated by heating at 70 C. for 10 min. Loading buffer 10 L (98% formamide, 10 mM EDTA 1 mg/mL xylene cyanol and 1 mg/mL bromophenol blue) was added to each reaction mixture, and an aliquot containing 2 pmoles of products (4 L) was resolved on 8% PAGE. An additional study was done testing just G-ONH.sub.2 at 250 M at 2, 5, 15, 30 and 60 min incubation at 37 C.

(29) Data are shown in FIG. 1. Terminal transferase was able to incorporate all four nucleoside triphosphates containing the 3-ONH.sub.2 block. In the purine buffer, dGTP-ONH.sub.2 appears to be incorporated more easily than dATP-ONH.sub.2. However even though this buffer is sold commercially to prefer standard purine nucleosides over pyrimidine nucleosides, dTTP-ONH.sub.2 is still incorporated. However, in purine buffer, dCTP-ONH.sub.2 is only slightly incorporated, and appears to inhibit the reaction at higher concentrations.

(30) In the pyrimidine buffer, dGTP-ONH.sub.2 and dATP-ONH.sub.2 both are successfully incorporated, as is dTTP-ONH.sub.2. dCTP-ONH.sub.2 is perhaps incorporated better, but again appears to have inhibitory activity.

(31) The results in FIG. 1 were obtained with triphosphates containing a small amount of 3-OH unblocked nucleoside triphosphates. The bands indicating incorporation of more than one nucleotide indicate this.

(32) A time course for the incorporation of GTP-ONH.sub.2 using TdT was then determined (FIG. 2). Nearly all of the primer has acquired an additional oligonucleotide) is seen. Thus, contacting oligonucleotide with the triphosphates is shown to be a way to incorporate the reversible terminator without the need of a template.

Example 2

(33) The oligonucleotide primer used here is the same as in Example 1. The aminoxytriphosphates were prepared on a resin, as taught in U.S. patent application Ser. No. 15/460,475, but under a release procedure using HONH.sub.2 elution, which did not minimize the presence of contaminating triphosphates with a free 3-OH group. This shows the results of this procedure. Data are shown in FIG. 3. The lanes are as follows:

(34) (a) The aminoxytriphosphate was synthesized on resin, with no Tris washes, and with immediate elution of the triphosphate with HONH.sub.2 after synthesis

(35) (b) The aminoxytriphosphate was synthesized on resin, with no Tris washes. The resin was then stored at room temperature overnight. Then, the triphosphate was eluted using HONH.sub.2 and used.

(36) (c) The aminoxytriphosphate was synthesized on resin, with three Tris washes overnight for one hour each. The aminoxytriphosphate was then eluted with HONH.sub.2.

(37) (d) The aminoxytriphosphate was synthesized on resin, which was then stored at room temperature overnight. The resin was then washed with Tris buffer (thrice, each for 1 hour). The aminoxytriphosphate was then eluted with HONH.sub.2.

(38) (e) The TdT extension was done with standard aminoxytriphosphate prepared in solution, a preparation that HPLC analysis showed contains 0.5% 3-OH.

(39) (f) The TdT extension was done with standard aminoxytriphosphate prepared in solution, following in situ deprotection of the acetoxime with HONH.sub.2, with buffer concentrations as in (a-d)

(40) (g) The same as in (f), but spiked with 2% TTP-OH containing a free 3-hydroxyl group.

(41) The TdT reaction was carried out as before with .sup.32P-labeled primer (0.5 M) in 1 in terminal transferase buffer (20 mM Tris-acetate, pH 7.9, 50 mM potassium acetate, 10 mM magnesium acetate, 1 mM dithiotheritol), 0.25 mM CoCl.sub.2, 200 M reversible terminator samples (a-f) and 10 Units of terminal deoxynucleotidyl transferase (TdT). Reactions were incubated at 37 C. for five and 50 min. Reactions were quenched by the addition of formamide quench buffer and were resolved on a 20% PAGE (FIG. 3).

Example 3

(42) The TdT reaction was executed with dTTP-ONH.sub.2 prepared as taught in U.S. patent application Ser. No. 15/460,475 using the same primer as above. Here, the aminoxytriphosphates were prepared by releasing TTP-ONH.sub.2 from the resin using MeONH.sub.2. Data are shown in FIG. 4.

(43) (a) TTP-ONH.sub.2, crude from resin synthesis, with MeONH.sub.2 buffer (4.2 mM).

(44) (b) TTP-ONH.sub.2, pure from solution synthesis, with MeONH.sub.2 buffer (5 mM).

(45) (c) TTP-ONH.sub.2, pure from solution synthesis, HPLC purified, no MeONH.sub.2 buffer, in pure water (4 mM).

(46) (d) dGTP-ONH.sub.2, pure from solution synthesis, HPLC purified, no MeONH.sub.2 buffer, in pure water (5 mM)

(47) As before, .sup.32P labeled primer (0.5 M) in 1 in terminal transferase buffer (20 mM Tris-acetate, pH 7.9, 50 mM potassium acetate, 10 mM magnesium acetate, 1 mM dithiotheritol), with and without 0.25 mM CoCl.sub.2, 200 M reversible terminator samples (a-d) and 10 Units of terminal deoxynucleotidyl transferase (TdT). Control samples containing TTP and ddTTP were also tested. Reactions were incubated at 37 C. 5 and 60 min. Reactions were quenched by the addition of formamide quench buffer and were resolved on a 20% PAGE (FIG. 4).

Example 4

(48) TABLE-US-00003 1) Terminal transferase 3- tailing studies Primer dhSSP1 SEQ ID NO 1 5-GCG TAA TAC GAC TCA CTA TGG ACG-3 Aminoxy samples terminator purity (at 260 nm) dATP-ONH.sub.2 67% dCTP-ONH.sub.2 74% TTP-ONH.sub.2 78% TTP-ONH.sub.2 in dH.sub.2O dGTP-ONH.sub.2 76% dSTP-ONH.sub.2

(49) Radiolabeled .sup.32P dhSSP1 (0.5 M) in 1 in terminal transferase buffer (20 mM Tris-acetate, pH 7.9, 50 mM potassium acetate, 10 mM magnesium acetate, 1 mM dithiotheritol), 0.25 mM CoCl.sub.2, 200 M reversible terminator samples or irreversible terminator and 0.5 U/L of terminal deoxynucleotidyl transferase (TdT) without and with the addition of pyrophosphatase (0.05 Units in 20 L reaction). Reactions were incubated at 37 C. 15 and 60 min. As a control, primer samples contained terminal transferase but lacked the addition of triphosphate. Reactions were quenched by the addition of formamide quench buffer and were resolved on a 20% PAGE (FIG. 7). Another gel was run to resolve the dSTP-ONH.sub.2 queried samples (FIG. 8).

(50) Separately, a reaction was run with radiolabeled .sup.32P dhSSP1 (0.1 M) in 1 in terminal transferase buffer (20 mM Tris-acetate, pH 7.9, 50 mM potassium acetate, 10 mM magnesium acetate, 1 mM dithiothreitol), 0.25 mM CoCl.sub.2, 200 M reversible terminator samples or irreversible terminator and 1 U/L of terminal deoxynucleotidyl transferase TdT). Reactions were incubated at 37 C. 15 and 60 min. As a control, primer samples contained terminal transferase but lacked the addition of triphosphate. Reactions were quenched by the addition of formamide quench buffer and were resolved on a 20% PAGE (FIG. 9).